An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
23actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-20 | actual | When the study began enrolling |
| Primary completion | 2025-11-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Interventions
- Drug: Amlitelimab — also filed as SAR445229
- Drug: Midazolam
- Drug: Caffeine
- Drug: Metoprolol
- Drug: Omeprazole
- Drug: Warfarin
Primary outcome
what the primary-completion date above is the date OFAUC and AUClast for CYP substrates
measured Baseline (Day 1 to Day 8) and Day 176 to Day 183
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed